Efficacy Comparison of Intravitreal Anti-VEGF Therapy for Three Subtypes of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis.
Efficacy Comparison of Intravitreal Anti-VEGF Therapy for Three Subtypes of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis.
复制标题
玻璃体内抗 VEGF 治疗三种亚型新生血管性年龄相关性黄斑变性的疗效比较：系统回顾和荟萃分析
DOI：
10.1155/2018/1425707
复制
发表时间：
2018
影响因子：
1.9
通讯作者：
Lu P
中科院分区：
文献类型：
--
作者：
Li J;Xu J;Chen Y;Zhang J;Cao Y;Lu P
目的 玻璃体内抗血管内皮生长因子（抗 VEGF）疗法已广泛用于治疗继发于年龄相关性黄斑变性（AMD）的新生血管（NV）。本研究旨在比较新生血管性年龄相关性黄斑变性 (nAMD) 不同亚型的疗效。方法 在 PubMed、Embase 和 Cochrane 图书馆中检索符合条件的研究。我们使用 Review Manager 5.3 和 Stata/SE 12.0 进行荟萃分析。结果 共有 24 项研究符合我们的纳入标准并纳入系统评价。 3个月时，1型、2型和3型的最小分辨率角（logMAR）改善的平均对数分别为-0.09、-0.18和-0.23，而平均黄斑厚度（MT）变化为-104.83、-130.76和-196.29μm。 12 个月时，糖尿病视网膜病变早期治疗研究 (ETDRS) 字母的平均变化分别为 6.38、8.12 和 9.37，而 MT 下降分别为 126.51、126.52 和 139.85μm。然而，无论是短期（p=0.0002）还是长期（p=0.01），仅 1 型和 3 型之间的视力改善存在统计学显着差异。结论 不同亚型的 nAMD 对 VEGF 抑制剂的反应性存在差异。当考虑到 3 个月和 12 个月的视力改善时，玻璃体内抗 VEGF 治疗对 3 型 nAMD 的疗效在统计学上优于 1 型。因此，病变亚型是治疗结果的预测因子，有助于指导预后。
Purpose Intravitreal antivascular endothelial growth factor (anti-VEGF) therapy has been widely used for the treatment of neovascularization (NV) secondary to age-related macular degeneration (AMD). This study aimed to compare the efficacy among different subtypes of neovascular age-related macular degeneration (nAMD). Methods PubMed, Embase, and the Cochrane Library were searched for eligible studies. We performed meta-analysis using Review Manager 5.3 and Stata/SE 12.0. Results A total of 24 studies met our inclusion criteria and were included in the systematic review. At 3 months, the mean logarithm of the minimum angle of resolution (logMAR) improvements were −0.09, −0.18, and −0.23 for type 1, 2, and 3, respectively, while the mean macular thickness (MT) changes were −104.83, −130.76, and −196.29 μm. At 12 months, the mean changes in Early Treatment of Diabetic Retinopathy Study (ETDRS) letters were 6.38, 8.12, and 9.37, while the MT decrease was 126.51, 126.52, and 139.85 μm, respectively. However, statistically significant difference was only found between type 1 and 3 in vision improvement, both in the short term (p=0.0002) and long term (p=0.01). Conclusions The reactivity to VEGF inhibitors varied among different subtypes of nAMD. The efficacy of intravitreal anti-VEGF therapy in type 3 nAMD was statistically better than type 1 when considering vision improvement at 3 and 12 months. Thus, the lesion subtype is a predictor for the treatment outcome which can help guide prognosis.
登录
查看更多内容
影响因子：
2.6
作者：
Castro-Navarro, Veronica;Cervera-Taulet, Enrique;Navarro-Palop, Catalina
通讯作者：
Navarro-Palop, Catalina
影响因子：
4.2
作者：
GASS, JDM
通讯作者：
GASS, JDM
影响因子：
1.6
作者：
Hufendiek, Katerina;Hufendiek, Karsten;Gamulescu, Maria-Andreea
通讯作者：
Gamulescu, Maria-Andreea
DOI：
10.2147/opth.s90932
发表时间：
2015
期刊：
Clinical ophthalmology (Auckland, N.Z.)
影响因子：
--
作者：
Kano M;Sekiryu T;Sugano Y;Oguchi Y;Ojima A;Itagaki K;Saito M
通讯作者：
Saito M
影响因子：
4.1
作者：
Costagliola, Ciro;Romano, Mario R.;Semeraro, Francesco
通讯作者：
Semeraro, Francesco